Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up-a real-world cost analysis.

ABSTRACT:

Background

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially life-threatening, systemic autoimmune disease with a high risk for relapse and treatment-related toxicity, making AAV a high-costs illness. This study aimed to identify clinical insights for clinicians on considering this costs burden.

Methods

We conducted a detailed, retrospective, single-centre, activity-based cost-analysis and identified clinical variables associated with increased costs. We analysed real-world costs incurred by the hospital between January 2018 and December 2019, omitting the outpatient pharmacy expenditures. Our cohort included both incident and prevalent AAV patients with at least 6 months of follow-up since diagnosis, indicating survival beyond initial

SUBMITTER: van Leeuwen JR 

PROVIDER: S-EPMC12448927 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature